Last reviewed · How we verify
Vaccinia virus: ACAM2000 smallpox vaccine
At a glance
| Generic name | Vaccinia virus: ACAM2000 smallpox vaccine |
|---|---|
| Sponsor | Emergent BioSolutions |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers (PHASE1)
- Evaluating the Human Immune Response to the JYNNEOS Vaccine (EARLY_PHASE1)
- MVA Post-Event: Administration Timing and Boost Study (PHASE1, PHASE2)
- Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia (PHASE3)
- Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT (PHASE4)
- High Dose IMVAMUNE® in Vaccinia-Naive Individuals (PHASE2)
- Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS (PHASE2)
- JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: